Ixazomib-Lenalidomide-Dexamethasone in Routine Clinical Practice: Effectiveness in Relapsed/refractory Multiple Myeloma

• DOI: 10.2217/fon-2020-1225
• Publication Date: 2021-03-26T09:10:32Z
• Authors: Roman Hájek; Jiří Minařík; Jan Straub; Luděk Pour; Alexandra Jungova; Jesus G Berdeja; Mario Boccadoro; Lucie Brozova; Andrew Spencer; Frits van Rhee; Jorge Vela-Ojeda; Michael A Thompson; Rafat Abonour; Ajai Chari; Gordon Cook; Caitlin L Costello; Faith E Davies; Vania T M Hungria; Hans C Lee; Xavier Leleu; Noemi Puig; Robert M Rifkin; Evangelos Terpos; Saad Z Usmani; Katja C Weisel; Jeffrey A Zonder; Magda Bařinová; Matyáš Kuhn; Jiří Šilar; Lenka Čápková; Kenny Galvez; Jin Lu; Jennifer Elliott; Dawn Marie Stull; Kaili Ren; Vladimír Maisnar
• Keywords: Ixazomib; Refractory (planetary science); Clinical Practice

Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma routine clinical practice. Patients & methods: Patient-level data from global, observational INSIGHT MM Czech Registry Monoclonal Gammopathies were integrated analyzed. Results: At cut-off, 263 patients 13 countries included. Median time diagnosis to start IRd was 35.8 months; median duration follow-up 14.8 months. Overall response rate 73%, progression-free survival, 21.2 months time-to-next therapy, 33.0 Ixazomib/lenalidomide dose reductions required 17%/36% patients; 32%/30% discontinued ixazomib/lenalidomide due adverse events. Conclusion: The practice are comparable those reported TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov).